Navidea Biopharmaceuticals Income Statement 2022-2008 | NAVB

Brief overview of revenue and earnings at Navidea Biopharmaceuticals

The overview follows changes across a five-year period. According to figures from Navidea Biopharmaceuticals, revenue changed from 1.8 million dollars to 65.7 thousand dollars over five years. The total change was −96.4%, with a CAGR of approximately −48.5%. Revenue ended the period on a sustained downward trend.

The gross result shifted from $1.8 million to −$119 thousand, or −106.6%. Cost of revenue developed less favorably than sales and pressured gross profitability. The gross margin was 99.8% at the start and −181.7% at the end. A lower margin indicates deterioration in the economics of the core business.

EBITDA was −13.6 million dollars at the beginning and −14 million dollars at the end of the period (−2.6%). Additional revenue translated efficiently into EBITDA. EBITDA margin was −753.7% at the start and −21328.6% at the end. A lower EBITDA share weakens the quality of the result.

Comparing the endpoints shows a move from 74.9 million dollars to −15.2 million dollars. Profit turned into a loss, the most concerning signal in the results.

Over the period, capitalization shifted from 1.2 billion dollars to 9 million dollars (−99.2%). The decline in value indicates softer investor confidence.

Summary assessment

The financial trajectory is weak and requires a cautious interpretation. The main areas of concern are a softer top-line trend, a low gross margin and pressure from direct costs. The key question is whether sales can be converted into sustainable profit.